| May 2008 · Vol. 20, No. 05 UPDATE
HOW DEVELOPMENTS ARE CHANGING PATIENT CARE
MENOPAUSE
Does estrogen therapy carry more risk than benefit? The answer depends, new data suggest, on the age of the patient, route of administration, and type of progestin.
|
Fast Track
Women in their 50s and early 60s can use HT without increasing their risk of CAD
|
|
Andrew
M.
Kaunitz,
MDDr. Kaunitz is Professor and Associate Chairman, Department of Obstetrics and Gynecology, at the University of Florida College of Medicine in Jacksonville. He serves on the OBG MANAGEMENT Board of Editors.
The author has received funding from Barr/Duramed, Bayer, and Warner Chilcott. He is a consultant for Barr/Duramed, Bayer, Warner Chilcott, Kenwood, Noven, and Johnson & Johnson. He holds stock with Sanofi Aventis and Procter & Gamble.
Does estrogen therapy carry more risk than benefit? The answer depends, new data suggest, on the age of the patient, route of administration, and type of progestin.
|
